1. SGLT2 Inhibitors: What Do the Data Mean for My Patients?

3. Program Goals

4. Renal Tubule Function and Effect of SGLT2 Inhibitors

5. Clinical Benefits of SGLT2 Inhibitors

6. SGLT2 Inhibitors Currently Approved in the United States and Europe

8. 2015 AACE Algorithm Placement of SGLT2 Inhibitors*,†

9. CANVAS Substudy Canagliflozin as an Add-on to Insulin Plus Metformin in Patients With T2D*

10. Long-term Study of Canagliflozin vs Glimepiride in Patients With T2D*

11. Study of Dapagliflozin Use in Patients With T2D in Routine Primary Care*

12. Safety Studies of Dapagliflozin and Saxagliptin added to Metformin in Patients With T2D

13. Study of Empagliflozin + Metformin as Initial Combination Therapy in Patients With T2D*

14. Effect of Baseline HbA1c on Weight Change With Empagliflozin + Linagliptin in Patients With T2D

15. Ongoing Cardiovascular Safety Studies

16. Data From the EMPA-REG OUTCOME Trial*

17. Diabetic Ketoacidosis With SGLT2 Inhibitor Treatment

18. Diabetic Ketoacidosis With SGLT2 Inhibitor Treatment (cont)

19. Abbreviations

20. Abbreviations (cont)

21. References

22. References (cont)

23. References (cont)

24. References (cont)

25. References (cont)

26. References (cont)

27. References (cont)

28. References (cont)